What NAD+ injections are, how subcutaneous NAD+ differs from IV drips and oral NMN/NR, typical research dosing, side effects, and how to source compounded…
Subcutaneous NAD+ injections deliver the NAD+ molecule directly, bypassing first-pass metabolism that limits oral NMN and NR. They are typically prepared by a licensed U.S. compounding partner as a 100–500 mg/mL solution, self-administered 1–3× per week. They are not FDA-approved drugs and are supplied for research, investigational, or licensed-professional use only.
NAD+ (nicotinamide adenine dinucleotide) is a coenzyme central to cellular energy production, DNA repair, and sirtuin activation. Levels decline with age, and the longevity field has spent the last decade looking for the most efficient way to restore them. Injectable NAD+ — typically subcutaneous self-administration from a compounded vial — is now the most-searched delivery method in the U.S. This guide covers what it is, how it compares to IV drips and oral precursors, typical research dosing, and how to vet a compounded supplier in 2026.
NAD+ is a coenzyme present in every living cell. It shuttles electrons in the mitochondrial electron transport chain (energy production), serves as a substrate for sirtuins (longevity-associated enzymes) and PARPs (DNA repair enzymes), and regulates circadian and metabolic signaling. Cellular NAD+ declines roughly 50% between ages 40 and 60 in observational studies — the basis for the entire 'NAD+ restoration' field.
Restoring NAD+ is mechanistically interesting because the molecule sits upstream of so many longevity pathways. Whether exogenous NAD+ delivery extends human healthspan is still under active clinical investigation; the published evidence is strongest for energy, recovery, and metabolic markers.
The most commonly reported side effect of subcutaneous NAD+ is local injection-site flushing or warmth — uncomfortable but transient. Faster push rates increase the sensation; slower administration reduces it. Some users report mild nausea or chest tightness at higher single doses, which typically resolves within minutes.
NAD+ has no recognized abuse potential and no known interactions with most peptide stacks, but published clinical data on long-horizon high-dose self-administration is still limited. As with all compounded peptides on this site, NAD+ is supplied for research, investigational, or licensed-professional use only.
All peptide products referenced are intended solely for research, investigational, or licensed professional use. They are not FDA-approved and are not intended to diagnose, treat, cure, or prevent any disease. Consult a licensed medical practitioner before any personal or clinical use.
Nicotinamide adenine dinucleotide. It is a coenzyme involved in energy production, DNA repair, and sirtuin activation in every cell of the body.
They are different delivery routes. IV achieves the highest plasma peak in one sitting but requires a clinical visit and is the most expensive. Subcutaneous injection achieves meaningful delivery at a fraction of the cost and can be self-administered, which is why it has become the dominant delivery method in 2026.
Common research protocols run 1–3 subcutaneous injections per week at 50–300 mg per session, often cycled. Optimal frequency depends on goals and practitioner guidance.
No. Compounded NAD+ is not an FDA-approved drug. It is prepared by licensed U.S. compounding partners for research, investigational, or licensed-professional use only.
Yes — NAD+ is part of our member catalog when supply allows. Current concentration and bulk-direct pricing are visible to members after sign-in with a VIP code.
Oral NMN and NR are NAD+ precursors that raise NAD+ via the salvage pathway. They are more convenient and lower-cost per day but lower-bioavailability than injection. Many users combine the two; the right choice is a conversation with a licensed practitioner.